Drugs / BRM421
BRM421
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not stated1 trial | ||||||
| — | NCT07422389 | — | limbal stem cell deficiency | BRIM Biotechnology Inc. | Available | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT07078955 Comparator | Dec 2025 → Nov 2026 expected | dry eye syndrome | BRIM Biotechnology Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05927428 Comparator | Jul 2024 → Aug 2025 overdue | neurotrophic keratopathy | BRIM Biotechnology Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT03066219 Comparator | Feb → May 2017 | dry eye syndrome | BRIM Biotechnology Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04343287 Comparator | Jan → Jun 2020 | dry eye syndrome | BRIM Biotechnology Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05695781 Comparator | Feb → Dec 2023 | dry eye syndrome | BRIM Biotechnology Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-04-24 | GrandPharma (China) Co., Ltd. | Regulatory 远大医药全球创新眼科药物GPN00136的中国II期临床试验申请获国家药监局批准 grandpharm.com ↗
近日，远大医药(0512.HK)用于治疗干眼症的小分子多肽药物GPN00136（BRM421）的II期临床试验申请已获得国家药监局批准，是本集团在眼科疾病治疗领域的又一项重要研发进展。 |
| 2023-02-27 | GrandPharma (China) Co., Ltd. | Regulatory 新序启 | 远大医药产品收获新进展（2月篇） grandpharm.com ↗
两款眼科产品获中国IND申请获受理 |
| 2023-01-30 | GrandPharma (China) Co., Ltd. | Regulatory 远大医药三款全球创新产品中国IND申请获受理，多板块业务协同推进 grandpharm.com ↗
近日，远大医药(00512.HK)在呼吸及重症抗感染以及眼科板块的三款全球创新药物的新药临床试验(IND)申请已获得国家药监局(NMPA)正式受理，为本集团在上述疾病治疗领域的重要研发进展。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-24 | GrandPharma (China) Co., Ltd. | 远大医药全球创新眼科药物GPN00136的中国II期临床试验申请获国家药监局批准 grandpharm.com ↗ |
| 2023-02-27 | GrandPharma (China) Co., Ltd. | 新序启 | 远大医药产品收获新进展（2月篇） grandpharm.com ↗ |
| 2023-01-30 | GrandPharma (China) Co., Ltd. | 远大医药三款全球创新产品中国IND申请获受理，多板块业务协同推进 grandpharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRM421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07422389 ↗ |
| Known as | BRM424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05927428 ↗ |
| Known as | Pedf derived peptide, 29-mer | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315015 ↗ |
| Route | Topical | “A topical drop of BRM421 ophthalmic solution.” NCT05695781 ↗ |